I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business. I guess the people who are afraid of finasteride and have made it some sort of devil drug must be ecstatic and overhyping any drug that isn’t finasteride but it doesn’t offer anything new and definitely not a “game changer” Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys. Access a live Likelihood of Approval and Phase Transition Success Rate Model – pyrilutamide dashboard for 12 months, with up-to-the-minute insights. Pharma, K. (2022, August 3). KINTOR Pharma announces completion of patient enrollment in phase II clinical trial of KX-826 for treatment of Androgenetic Alopecia in the US. Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US. Retrieved October 1, 2022 .

Likelihood of Approval and Phase Transition Success Rate

INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2022, KINTOR PHARMACEUTICAL LIMITED (2022). Accessed online: https://www1.hkexnews.hk/listedco/listconews/sehk/2022/0829/2022082902004.pdf The primary endpoint is the change from baseline in non- vellus target area hair count (TAHC) at the end of week 24. The drug will be dosed at 10 mg (0.5% BID) per patient per day in the trial. [4] Adverse effects [ edit ] That's why i was curious that if it was combined possibly with Finasteride for an experiment whether maybe it could be a more potent solution to the issue of Minoxodil. With topical or Oral Minoxodil we know that you have to indefinitely continue that treatment to maintain the hair it regrows even if you take Finasteride but i am curious whether people who regrow hair with the use of both Finasteride and Pyrilutamide could hypothetically maintain all the hair say by switching over to just one rather than losing ground like people usually do when they stop Minoxidil. Use PTSR and LOA information and event-driven changes for your investment decisions to generate alphaPyrilutamide is a topical anti-androgen. The clinical trials done so far have shown that it does not decrease systemic androgen levels. Thus, it is unlikely to cause unwanted adverse drug reactions that are usually seen in patients using oral 5-alpha reductase inhibitors – decreased libido, erectile dysfunction, and depression being the most notable ones. The drug innovator is Kintor Pharmaceutical Limited, known for developing and commercializing innovative treatments for androgen receptor-related diseases like androgenetic alopecia, acne vulgaris, and certain cancers. There are ongoing clinical trials to prove its efficacy and safety, which may eventually lead to better accessibility and FDA approval. Right now, joining a pyrilutamide clinical trial is highly unlikely as enrollment for men in the United States and women in China are currently closed. You’d only be considered as a participant if you were a man with moderate pattern hair loss symptoms living in China.

Pyrilutamide 0.5% solution - 3x30ml bottles – RUdirect Pyrilutamide 0.5% solution - 3x30ml bottles – RUdirect

Pattern hair loss affects 16% of men between the ages of 18 and 29. And about 25% of American men start seeing the first signs of androgenetic alopecia before they’re 21. If you're one of these guys, you'll likely see a number of hair loss symptoms, including slowed hair growth, hair thinning, an increase in the amount of fragile or short hairs on your head, and loss of hair around your hairline, temples, and top of your head.Most recently, the results from the phase-2 trial conducted in the USA were released in May 2023. It was a randomized, double-blind, placebo-controlled, and parallel-group study designed to evaluate the efficacy and safety of pyrilutamide for the treatment of male pattern alopecia. A total of 123 patients were enrolled in the study. From this, 93 patients were randomly assigned to different dosage groups – 0.25% once daily, 0.5% once daily, and 0.5% twice daily. The remaining 30 patients were randomly assigned to placebo groups. The company said in the study KX-826 demonstrated clinically meaningful and statistically significant improvement in hair growth as measured by target area non-vellus hair count (TAHC). In addition, its safety profile was favorable.